DiagnoCure Directors Re-Elected by Shareholders at Annual and Special Meeting of Shareholders
29 Abril 2013 - 5:27PM
OTC Markets
DiagnoCure Directors Re-Elected by Shareholders at Annual and
Special Meeting of Shareholders
#ReleaseContent TABLE
{
BORDER-COLLAPSE: collapse
}
TR.cnwUnderlinedCell TD
{
BORDER-BOTTOM: #000000 1px solid
}
TR.cnwDoubleUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px double
}
TR.cnwBoldUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px solid
}
TD.cnwUnderlinedCell
{
BORDER-BOTTOM: #000000 1px solid
}
TD.cnwDoubleUnderlinedCell
{
BORDER-BOTTOM: #000000 3px double
}
TD.cnwBoldUnderlinedCell
{
BORDER-BOTTOM: #000000 3px solid
}
#ReleaseContent TABLE.cnwBorderedTable TD
{
BORDER-RIGHT: black 1px solid;
PADDING-RIGHT: 2px;
BORDER-TOP: black 1px solid;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
BORDER-LEFT: black 1px solid;
PADDING-TOP: 2px;
BORDER-BOTTOM: black 1px solid;
BORDER-COLLAPSE: collapse
}
#ReleaseContent TABLE TD
{
PADDING-RIGHT: 2px;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
PADDING-TOP: 2px
}
DiagnoCure Directors Re-Elected by Shareholders at Annual and
Special Meeting of Shareholders
PR Newswire
QUEBEC CITY, April 29, 2013
QUEBEC CITY, April 29, 2013 /PRNewswire/ - DiagnoCure Inc.
(TSX: CUR)
(OTCQX: DGCRF) is pleased to announce that Dr. Yves Fradet, Dr. Louise
Proulx, Mr. Andrew Sheldon,
Dr. Jacques Simoneau, and Dr.
Vincent R.
Zurawski, were re-elected by shareholders at the 2013 annual
and
special meeting of shareholders, held today in Montreal.
Shareholders also reappointed Ernst & Young as auditors of the
company,
approved and ratified amendments to the articles of
DiagnoCure,
approved and ratified the new by-laws of the company - including
the
advanced notice by-law, and approved all unallocated options
under
DiagnoCure's stock option plan.
Dr. Yves Fradet, Chairman of the
Board stated, "We appreciate the
support of our shareholders in re-electing all of DiagnoCure's
director
nominees. Rest assured, your board and management team will
continue to
work to enhance and maximize value for shareholders."
"We will continue to be receptive to feedback from all of our
shareholders." said Dr. Fradet.
The election results for the Board of directors are as
follows:
|
For
|
Withheld
|
DiagnoCure nominees
|
|
|
Yves Fradet
|
15,064,450
|
11,584,571
|
Louise Proulx
|
15,195,476
|
11,573,041
|
Andrew J. Sheldon
|
15,155,676
|
11,612,841
|
Jacques Simoneau
|
15,194,976
|
11,573,041
|
Vincent R. Zurawski
|
15,167,576
|
11,600,941
|
|
|
|
Dissident nominees
|
|
|
Pierre Dozois
|
5,385,250
|
22,797,322
|
Paul Guay
|
5,385,250
|
22,797,322
|
Hans Mäder
|
5,385,250
|
22,797,322
|
|
|
|
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation
that
develops and commercializes high-value cancer diagnostic tests
that
increase clinician and patient confidence in making critical
treatment
decisions. In 2008, the Corporation launched a colorectal
cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC
is
currently available for licensing. The Corporation has granted
a
worldwide exclusive license to Gen-Probe, now a wholly-owned
subsidiary
of Hologic Inc. operating as Hologic Gen-Probe, for the development
and
commercialization of a prostate cancer test using PCA3,
DiagnoCure's
proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA®
PCA3
test is commercialized in Europe
under CE mark and is approved for
commercialization in Canada and
the United States. For more
information, please visit www.diagnocure.com.
Forward?looking statements
This release may contain forward?looking statements that involve
known
and unknown risks, uncertainties and assumptions that may cause
actual
results to differ materially from those expected.
Forward-looking
statements can be identified by the use of the conditional or
forward-looking terminology such as "anticipates", "assumes",
"believes", "estimates", "expects", "intend", "may", "plans",
"projects", "should", "will", or the negative thereof or other
variations thereon. Forward-looking statements also include any
other
statements that do not refer to historical facts. All such
forward-looking statements are made pursuant to the
"safe-harbour"
provisions of applicable Canadian securities laws. By their
very
nature, forward?looking statements are based on expectations
and
hypotheses and also involve risks and uncertainties, known and
unknown,
many of which are beyond DiagnoCure's control. Forward-looking
statements are presented for the purpose of assisting investors
and
others in understanding certain key elements of the
Corporation's
current objectives, strategic priorities, expectations and plans,
and
in obtaining a better understanding of the Corporation's business
and
anticipated operating environment. Readers are cautioned that
such
information may not be appropriate for other purposes and that
they
should not place undue reliance on these forward?looking
statements.
For instance, any forward-looking statements regarding the outcome
of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA® PCA3, are based
on
management expectations and such outcome may vary materially
depending
on global political and economic conditions, dependence on
collaboration partners, uncertainty of healthcare reimbursement,
and
marketing and distribution challenges. In addition, the reader
is
referred to the applicable general risks and uncertainties
described in
DiagnoCure's most recent Annual Information Form under the
heading
"Risk Factors". DiagnoCure undertakes no obligation to publicly
update
or revise any forward?looking statements contained herein
unless
required by the applicable securities laws and
regulations.
SOURCE DiagnoCure inc.
Diagnocure (CE) (USOTC:DGCRF)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Diagnocure (CE) (USOTC:DGCRF)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
